Valuation: Moderna, Inc.

Market Cap 80.65B 73.48B 68.02B 61.53B 115B 7,533B 121B 822B 326B 4,070B 303B 296B 12,894B P/E 2026 *
-27.3x
P/E 2027 * -44.8x
Enterprise Value 75.8B 69.06B 63.93B 57.82B 108B 7,079B 114B 773B 307B 3,825B 284B 278B 12,117B EV / Sales 2026 *
31.4x
EV / Sales 2027 * 28.5x
Free-Float
92.75%
Yield 2026 *
-
Yield 2027 * -
1 day+1.29%
1 week-13.84%
Current month-10.10%
1 month-12.15%
3 months+14.31%
6 months+335.98%
Current year+575.92%
1 week 189.98
Extreme 189.98
222.42
1 month 179.53
Extreme 179.53
280.8
Current year 29.81
Extreme 29.81
280.8
1 year 22.28
Extreme 22.28
280.8
3 years 22.28
Extreme 22.28
280.8
5 years 22.28
Extreme 22.28
376.65
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 63 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap. Importance
15/10/26 Exercice

Chairperson

192,049 0.0481%
5/10/26 Other

Chief Operating Officer

125,000 0.0313%
5/10/26 Exercice

Chief Financial Officer

3,612 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
+1.29%-13.84%+724.36%+160.77% 79.63B
-2.29%-5.34%+28.73%+128.34% 1,232B
-2.04%-5.78%+31.91%+78.34% 656B
-0.86%-3.71%+21.74%+105.02% 506B
-1.04%-1.80%+28.69%+68.01% 382B
-3.61%-9.62%+39.73%+30.53% 340B
-3.22%-5.20%+24.48%+51.30% 294B
-2.51%-4.49%-2.15%+29.67% 278B
-1.14%-6.05%+28.16%+65.35% 240B
-1.45%-0.85%+30.03%+120.72% 210B
Average -1.69%-4.16%+95.57%+83.80% 422B
Weighted average by Cap. -1.98%-3.02%+40.10%+89.18%

Financials

2026 *2027 *
Net sales 2.41B 2.2B 2.04B 1.84B 3.46B 225B 3.62B 24.61B 9.76B 122B 9.06B 8.87B 386B 2.69B 2.45B 2.27B 2.05B 3.85B 251B 4.03B 27.4B 10.87B 136B 10.08B 9.87B 430B
Net income -2.9B -2.65B -2.45B -2.22B -4.16B -271B -4.35B -29.61B -11.75B -147B -10.9B -10.67B -464B -1.68B -1.53B -1.42B -1.28B -2.4B -157B -2.51B -17.11B -6.79B -84.72B -6.3B -6.17B -268B
Net Debt -4.86B -4.42B -4.1B -3.71B -6.95B -454B -7.27B -49.51B -19.64B -245B -18.22B -17.84B -776B -3.93B -3.58B -3.31B -3B -5.62B -367B -5.89B -40.06B -15.89B -198B -14.74B -14.43B -628B
Projected Income Statement - Annual - Moderna, Inc.
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
19/11/26 US$199.33 +1.29% 8,204,149
18/11/26 US$196.79 -4.84% 6,986,325
17/11/26 US$206.80 -3.93% 8,277,036
16/11/26 US$215.27 -3.63% 7,023,751
13/11/26 US$223.37 -3.45% 8,085,638
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Moderna, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
199.33USD
Average target price
164.53USD
Spread / Average Target
-17.46%
  1. Stock Market
  2. Stocks
  3. MRNA Stock